Aptiom and Diamox Sequels

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Treatment with eslicarbazepine may occasionally cause blood sodium levels to get too low, a condition known as hyponatremia, and using it with acetaZOLAMIDE can increase that risk. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should seek medical attention if you experience nausea, vomiting, headache, lethargy, irritability, difficulty concentrating, memory impairment, confusion, muscle spasm, weakness or unsteadiness, as these may be symptoms of hyponatremia. More severe cases may lead to hallucination, fainting, seizure, coma, and even death. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with other medications that can lower serum sodium levels such as diuretics, selective serotonin reuptake inhibitors (SSRIs), and serotonin-noradrenaline reuptake inhibitors (SNRIs) may potentiate the risk of hyponatremia associated with eslicarbazepine. In controlled clinical trials, 1% and 1.5% of patients treated with eslicarbazepine acetate 800 mg/day and 1200 mg/day, respectively, had at least one serum sodium value less than 125 mEq/L, compared to none of the patients receiving placebo. Additionally, 5.1% of eslicarbazepine-treated patients experienced decreases greater than 10 mEq/L, versus 0.7% of placebo-treated patients. These effects were dose-related and generally appeared within the first 8 weeks of treatment, with onset as early as after 3 days. Serious, life-threatening complications have included seizures, dehydration from severe nausea and vomiting, severe gait instability, and injury. Hospitalization and discontinuation of eslicarbazepine therapy were required in some cases. Concurrent hypochloremia was also present in patients with hyponatremia.

MANAGEMENT: Routine monitoring of serum sodium and chloride levels should be considered during maintenance treatment with eslicarbazepine acetate and concomitant use of other medications known to decrease serum sodium levels. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Depending on the severity of hyponatremia, dosage reduction or discontinuation of eslicarbazepine acetate and other medications may be required, and appropriate medical intervention instituted as necessary.

Aptiom

Generic Name: eslicarbazepine

Brand name: Aptiom

Synonyms: n.a.

What is Aptiom?

Diamox Sequels

Generic Name: acetazolamide

Brand name: Diamox, Diamox Sequels

Synonyms: n.a.

What is Diamox Sequels?